Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Q4 Revenues Rise 12 Percent, Net Loss Halved

This article has been updated from a previous version to include marketable securities as part of Gene Logic's liquid assets.

NEW YORK, Feb. 24 (GenomeWeb News) - Gene Logic reported today that 2005 fourth quarter revenue rose 12 percent in 2004 to $22.4 million from $20.1 million in the fourth quarter of 2004.

Gene Logic's genomics services business reported its fourth profitable quarter in a row and a 27-percent increase in revenue to $17.5 million from $13.8 million in the fourth quarter of 2004. 

Revenues for the firm's nonclinical services group fell, however, to $4.7 million from $6.3 million in the year-ago period, while the newly launched drug-repositioning business posted $272,000 in revenue for the quarter. 

The company's losses narrowed in the fourth quarter to $2.1 million, or $.07 per share, from $4.0 million, or $.13 per share, a year ago. Losses reflect the final purchase price allocation of $300,000 related to purchased R&D write-off in connection with the company's purchase of the Horizon drug-repositioning business from Millenium Pharmaceuticals in 2004.

R&D spending increased to $2.2 million from $1.1 million in the year-ago period.

As of Dec. 31, the company had approximately $82.1 million in combined cash, cash equivalents and marketable securities available-for-sale. Of that, $44.0 million is in the form of cash and cash equivalents.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.